Followers | 130 |
Posts | 7536 |
Boards Moderated | 1 |
Alias Born | 02/25/2014 |
Friday, March 13, 2020 12:48:45 PM
Paul is responsible for opening up the Japanese market to US drug companies
Inabata Pharmaceuticals becomes a significant provider of pharmaceuticals and API and merges with Sumitomo Pharmaceuticals in 1983. Licensing activity begins in 1996 with Sumitomo Pharmaceuticals, through the negotiations of Investment Banker, Paul M. Michaels, licenses Ambisome and Danisome for the Asian marketplace from a U.S. Pharmaceutical company. This is the beginning of business licensing U.S. developed drugs for the Japanese market. Additionally, an Orphan drug business is created with the assistance of Paul M. Michaels with his Japanese counterparts called Nobelpharma. Co.Ltd. The first licensed product, from Teva Pharmaceuticals USA, is for the treatment of Wilson's disease in Japan. This transaction was negotiated and completed by Paul Michaels.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM